<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1764</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2024-20-1-140-145</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL NOTES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical case of urachal carcinoma treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Клинический случай лечения карциномы урахуса</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8473-6645</contrib-id><name-alternatives><name xml:lang="en"><surname>Nurgaliyev</surname><given-names>N. S.</given-names></name><name xml:lang="ru"><surname>Нургалиев</surname><given-names>Н. С.</given-names></name></name-alternatives><address><country country="KZ">Kazakhstan</country></address><bio xml:lang="en"><p>Nurzhan S. Nurgaliyev.</p><p>31 Nauryzbay Batyra St., Almaty 050000</p></bio><bio xml:lang="ru"><p>Нургалиев Нуржан Серикович - ведущий врач-онкоуролог, хирург клиники Almaty SEMA Hospital; доктор медицинских наук.</p><p>050000 Алматы, ул. Наурызбай Батыра, 31</p><p>Тел.: +77017780108</p></bio><email>nurgaliyev.ns@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-1163-5973</contrib-id><name-alternatives><name xml:lang="en"><surname>Ukolova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Уколова</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="KZ">Kazakhstan</country></address><bio xml:lang="en"><p>31 Nauryzbay Batyra St., Almaty 050000</p></bio><bio xml:lang="ru"><p>Уколова Елена Андреевна - врач-онколог, химиотерапевт клиники.</p><p>050000 Алматы, ул. Наурызбай Батыра, 31</p></bio><email>kroter_elena@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1456-0047</contrib-id><name-alternatives><name xml:lang="en"><surname>Satbaeva</surname><given-names>E. B.</given-names></name><name xml:lang="ru"><surname>Сатбаева</surname><given-names>Э. Б.</given-names></name></name-alternatives><address><country country="KZ">Kazakhstan</country></address><bio xml:lang="en"><p>7a Utepova St., Almaty 050060</p></bio><bio xml:lang="ru"><p>Сатбаева Эльвира Булатовна - заведующая Лаборатории иммуногистохимической и молекулярно-генетической диагностики, кандидат медицинских наук.</p><p>050060 Алматы, ул. Утепова, 7а</p></bio><email>somaka@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aydarkulov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Айдаркулов</surname><given-names>А. A.</given-names></name></name-alternatives><address><country country="KZ">Kazakhstan</country></address><bio xml:lang="en"><p>31 Nauryzbay Batyra St., Almaty 050000</p></bio><bio xml:lang="ru"><p>050000 Алматы, ул. Наурызбай Батыра, 31</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rakhimov</surname><given-names>G. T.</given-names></name><name xml:lang="ru"><surname>Рахимов</surname><given-names>Г. Т.</given-names></name></name-alternatives><address><country country="KZ">Kazakhstan</country></address><bio xml:lang="en"><p>31 Nauryzbay Batyra St., Almaty 050000</p></bio><bio xml:lang="ru"><p>050000 Алматы, ул. Наурызбай Батыра, 31</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>Almaty SEMA Hospital</institution></aff><aff-alternatives id="aff2"><aff><institution xml:lang="en">Almaty Oncology Center</institution></aff><aff><institution xml:lang="ru">Алматинский онкологический центр</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-05-18" publication-format="electronic"><day>18</day><month>05</month><year>2024</year></pub-date><volume>20</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>140</fpage><lpage>145</lpage><history><date date-type="received" iso-8601-date="2024-01-08"><day>08</day><month>01</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-04-02"><day>02</day><month>04</month><year>2024</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1764">https://oncourology.abvpress.ru/oncur/article/view/1764</self-uri><abstract xml:lang="en"><p>Urachal carcinoma is a rare pathology of the lower urinary tract. In a review of the largest case series, five-year overall survival was about 50 %. The poor prognosis is mainly attributed to advanced stage of the disease due to relative absence of symptoms in localized disease, the difficulty of identification by cystoscopy, and the lack of clear consensus regarding investigation and treatment of localized and advanced disease.</p><p>We report a case of treatment of a 46-year-old patient with primary urachal carcinoma. Cystoscopy revealed a lesion on the bladder closer to the apex. Magnetic resonance imaging of the pelvic organs revealed a picture of a malignant neoplasm of the bladder with growth into the paravesical tissue and the anterior wall of the bladder. The patient underwent surgery followed by adjuvant chemotherapy.</p></abstract><trans-abstract xml:lang="ru"><p>Рак урахуса является редкой патологией нижних мочевых путей. В обзоре самой большой серии случаев 5-летняя общая выживаемость составляет около 50 %. Плохой прогноз в основном объясняется поздней стадией из-за относительного отсутствия симптомов при локализованном заболевании, сложности идентификации с помощью цистоскопии и отсутствия четкого консенсуса в отношении исследования и лечения локализованных и поздних стадий заболевания.</p><p>В статье представлен случай лечения пациентки 46 лет с первичной карциномой урахуса. По данным цистоскопии ближе к верхушке выявлено образование мочевого пузыря. При проведении магнитно-резонансной томографии органов малого таза – картина злокачественного новообразования мочевого пузыря с прорастанием в паравезикальную клетчатку и переднюю стенку мочевого пузыря. Пациентке проведено хирургическое вмешательство с последующей адъювантной химиотерапией.</p></trans-abstract><kwd-group xml:lang="en"><kwd>urachal carcinoma</kwd><kwd>bladder cancer</kwd><kwd>chemotherapy of urachal cancer</kwd><kwd>treatment of urachal carcinoma</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>карцинома урахуса</kwd><kwd>рак мочевого пузыря</kwd><kwd>химиотерапия рака урахуса</kwd><kwd>лечение карциномы урахуса</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Begg R.C. Theurachus: itsanatomy, histology and development. J Anat 1930;64:170–83.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>WHO classification of tumours series. 5th edn. Vol. 8. Available at: https://tumourclassification.iarc.who.int/chapters/36.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Szarvas T., Modos O., Niedworok C. et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma – a comprehensive review with meta-analysis of 1010 cases. Urol Oncol 2016;34:388–98. DOI: 10.1016/j.urolonc.2016.04.012</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>https://www.pathologyoutlines.com/topic/bladderadenourachal.html.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Molina J.R., Quevedo J.F., Furth A.F. et al. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer 2007;110(11):2434–40. DOI: 10.1002/cncr.23070</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Siefker-Radtke A. Urachal adenocarcinoma: a clinician’s guide for treatment. Semin Oncol 2012;39(5):619–24. DOI: 10.1053/j.seminoncol.2012.08.011</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Sheldon C.A., Clayman R.V., Gonzalez R. et al. Malignant urachal lesions. J Urol 1984;131(1):1–8. DOI: 10.1016/s0022-5347(17)50167-6</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Krysiewicz S. Diagnosis of urachal carcinoma by computed tomography and magnetic resonance imaging. Clin Imaging 1990;14(3):251–4. DOI: 10.1016/0899-7071(90)90085-p</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Siefker-Radtke A.O., Gee J., Shen Y. et al. Multimodality management of urachal carcinoma: the M.D. Anderson Cancer Center experience. J Urol 2003;169(4):1295–8. DOI: 10.1097/01.ju.0000054646.49381.01</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Henly D.R., Farrow G.M., Zincke H. Urachal cancer: role of conservative surgery. Urology 1993;42(6):635–9. DOI: 10.1016/0090-4295(93)90526-g</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mylonas K.S., O’Malley P., Ziogas I.A. et al. Malignant urachal neoplasms: a population-based study and systematic review of literature. Urol Oncol 2017;35(1):33e11–9. DOI: 10.1016/j.urolonc.2016.07.021</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kikuchi M., Kamei S., Morirama Y. et al. Case of urachal cancer treated by neoadjuvant chemotherapywith FOLFOX4 (oxaliplatin, 5-FU and leukovolin). Hinyokika Kiyo 2008;54(8):557–9.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kume H., Tomita K., Takahashi S., Fukutani K. Irinotecan as a new agent for urachal cancer. Urol Int 2006;76(3):281–2. DOI: 10.1159/000091635</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Galsky M.D., Iasonos A., Mironov S. et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 2007;69:255–9. DOI: 10.1016/j.urology.2006.10.029</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Jung H.A., Sun J.M., Park S.H. et al. Treatment outcome and relevance of palliative chemotherapy in urachalcancer. Chemotherapy 2014;60(2):73–80. DOI: 10.1159/000368071</mixed-citation></ref></ref-list></back></article>
